indomethacin has been researched along with Infant, Newborn, Diseases in 43 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Infant, Newborn, Diseases: Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The effects of acetaminophen in pregnancy and in the newborn have not been studied extensively; when ingested in usual therapeutic doses, the available data have shown no adverse effects." | 7.66 | Effects of aspirin and acetaminophen in pregnancy and in the newborn. ( Rudolph, AM, 1981) |
| "Two twins born to a mother who had been treated with Indomethacin at the end of pregnancy presented with variable but transitory hypoxemia." | 7.66 | [Twin pregnancy, indomethacin and neonatal cyanosis (author's transl)]. ( Boulley, AM; Dehan, M; Gabilan, JC; Hernandorena, X; Laudignon, N; Lhermitte, C; Ropert, JC; Vial, M, 1980) |
| "(2) Multiple analyses showed that patent ductus arteriosus(PDA) (odds ratio[OR] = 5." | 5.91 | Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study. ( Cui, S; Han, X, 2023) |
| "Expectant management for PDA in extremely premature infants was noninferior to early ibuprofen treatment with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks' postmenstrual age." | 5.69 | Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. ( Avino, D; de Baat, T; De Bisschop, B; de Boode, WP; de Vries, WB; Derriks, F; Dijk, PH; Dijkman, KP; Donders, R; Henriksen, TB; Hocq, C; Hundscheid, T; Kooi, EMW; Kroon, AA; Kyng, KJ; Meeus, M; Mulder, AL; Mulder-de Tollenaer, SM; Nuytemans, DHGM; Onland, W; van Kaam, AH; Van Overmeire, B; Vijlbrief, DC; Villamor, E; Visser, R; Zecic, A, 2023) |
| "Indomethacin was discontinued beyond the 33rd week of gestational age." | 5.29 | [Has the use of indomethacin during pregnancy consequences in newborn infants? Prospective study of 83 pregnant women and 115 newborn infants]. ( Blot, P; Boissinot, C; Carbillon, L; de Gayffier, A; Germain, JF; Jacqz-Aigrain, E; Oury, JF; Sibony, O, 1994) |
| "Indomethacin purportedly arrests premature labor by inhibiting the production of prostaglandins." | 5.26 | Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. ( Manchester, D; Margolis, HS; Sheldon, RE, 1976) |
| "We reviewed the medical records of seven children with congenital nephrotic syndrome (CNS) treated by unilateral nephrectomy, captopril, and indomethacin since 1990." | 3.72 | Management of congenital nephrotic syndrome. ( Kovacevic, L; Reid, CJ; Rigden, SP, 2003) |
| " The effects of acetaminophen in pregnancy and in the newborn have not been studied extensively; when ingested in usual therapeutic doses, the available data have shown no adverse effects." | 3.66 | Effects of aspirin and acetaminophen in pregnancy and in the newborn. ( Rudolph, AM, 1981) |
| "Two twins born to a mother who had been treated with Indomethacin at the end of pregnancy presented with variable but transitory hypoxemia." | 3.66 | [Twin pregnancy, indomethacin and neonatal cyanosis (author's transl)]. ( Boulley, AM; Dehan, M; Gabilan, JC; Hernandorena, X; Laudignon, N; Lhermitte, C; Ropert, JC; Vial, M, 1980) |
| "Women in acute preterm labor with cervical dilatation 1-6 cm were randomized to receive one of three first-line tocolytic drugs." | 2.77 | Effect of antenatal tocolysis on neonatal outcomes. ( Briery, CM; Keiser, SD; Klauser, CK; Kosek, MA; Martin, RW; Morrison, JC, 2012) |
| "Indomethacin was significantly more effective than placebo in inhibition of premature labor during a 24-hour course of therapy, with treatment failure during therapy occurring in only one of 15 indomethacin-treated patients compared to nine of 15 placebo-treated patients (p less than 0." | 2.65 | The inhibition of premature labor with indomethacin. ( Blake, DA; Dubin, NH; Egner, PG; Kumor, KM; Niebyl, JR; Robinson, JC; White, RD, 1980) |
| "Persistent patent ductus arteriosus (PDA) is a common pathology in the preterm whose traditional treatment has been indomethacin." | 2.44 | [Ibuprofen versus indomethacin in the preterm persistent patent ductus arteriosus therapy: review and meta-analysis]. ( Fernández Gilino, C; Gimeno Navarro, A; Gutiérrez Laso, A; Izquierdo Macián, I; Modesto Alapont, V; Morcillo Sopena, F, 2007) |
| "Although our pooled results did not identify significantly increased risks of adverse effects, the limited statistical power of published randomized trials does not allow us to exclude the possibility that indomethacin tocolysis increases the risk of adverse neonatal outcomes." | 2.43 | Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. ( Kaunitz, AM; Loe, SM; Sanchez-Ramos, L, 2005) |
| "(2) Multiple analyses showed that patent ductus arteriosus(PDA) (odds ratio[OR] = 5." | 1.91 | Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study. ( Cui, S; Han, X, 2023) |
| "Indomethacin has been administered for longer durations to prolong gestation in extreme prematurity." | 1.43 | Perinatal Outcomes after Short versus Prolonged Indomethacin for Tocolysis in Women with Preterm Labor. ( Behnia, F; Costantine, M; Dutta, EH; Harirah, H; Saade, G, 2016) |
| "Bartter syndrome is an autosomal recessive renal tubulopathy that presents with hypokalemic, hypochloremic metabolic alkalosis associated with increased urinary loss of sodium, potassium, calcium and chloride." | 1.42 | A Rare Disorder with Common Clinical Presentation: Neonatal Bartter Syndrome. ( Al-Muhaizae, M; Hussain, S; Tarar, SH, 2015) |
| "Antenatal Bartter syndrome is characterized by severe polyhydramnios in mother leading to premature delivery." | 1.40 | Antenatal Bartter syndrome. ( Afzal, M; Anwar, V; Azam, S; Khan, EA; Khan, WA; Rafiq, S; Yaqoob, A, 2014) |
| "Indomethacin was discontinued beyond the 33rd week of gestational age." | 1.29 | [Has the use of indomethacin during pregnancy consequences in newborn infants? Prospective study of 83 pregnant women and 115 newborn infants]. ( Blot, P; Boissinot, C; Carbillon, L; de Gayffier, A; Germain, JF; Jacqz-Aigrain, E; Oury, JF; Sibony, O, 1994) |
| "Symptomatic patent ductus arteriosus (sPDA) may occur in up to 50% of very-low-birth-weight (VLBW, less than or equal to 1500 g) infants." | 1.28 | Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989. ( Mouzinho, AI; Risser, R; Rosenfeld, CR, 1991) |
| "The chronic use of prostaglandin synthetase inhibitors is reported in a pregnant patient with severe juvenile rheumatoid arthritis." | 1.26 | Oligohydramnios and transient neonatal anuria: a possible association with the maternal use of prostaglandin synthetase inhibitors. ( Cantor, B; Nelson, RM; Stein, GH; Tyler, T, 1980) |
| "Ibuprofen was more effective than indomethacin in the high mortality model (lethal dose for 90% survival of group)." | 1.26 | Improved survival in the suckling rat model of group B streptococcal sepsis after treatment with nonsteroidal anti-inflammatory drugs. ( Fletcher, JR; Miller, MK; Short, BL, 1982) |
| "Indomethacin purportedly arrests premature labor by inhibiting the production of prostaglandins." | 1.26 | Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. ( Manchester, D; Margolis, HS; Sheldon, RE, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (58.14) | 18.7374 |
| 1990's | 4 (9.30) | 18.2507 |
| 2000's | 5 (11.63) | 29.6817 |
| 2010's | 5 (11.63) | 24.3611 |
| 2020's | 4 (9.30) | 2.80 |
| Authors | Studies |
|---|---|
| Hundscheid, T | 2 |
| Onland, W | 2 |
| Kooi, EMW | 2 |
| Vijlbrief, DC | 2 |
| de Vries, WB | 2 |
| Dijkman, KP | 2 |
| van Kaam, AH | 2 |
| Villamor, E | 2 |
| Kroon, AA | 2 |
| Visser, R | 2 |
| Mulder-de Tollenaer, SM | 2 |
| De Bisschop, B | 2 |
| Dijk, PH | 2 |
| Avino, D | 2 |
| Hocq, C | 2 |
| Zecic, A | 2 |
| Meeus, M | 2 |
| de Baat, T | 2 |
| Derriks, F | 2 |
| Henriksen, TB | 2 |
| Kyng, KJ | 2 |
| Donders, R | 2 |
| Nuytemans, DHGM | 2 |
| Van Overmeire, B | 2 |
| Mulder, AL | 2 |
| de Boode, WP | 2 |
| Han, X | 1 |
| Cui, S | 1 |
| Albert, R | 1 |
| Lee, A | 1 |
| Lingappan, K | 1 |
| Brichta, C | 1 |
| Hoppe, KK | 1 |
| Lasarev, MR | 1 |
| Harer, MW | 1 |
| Afzal, M | 1 |
| Khan, EA | 1 |
| Khan, WA | 1 |
| Anwar, V | 1 |
| Yaqoob, A | 1 |
| Rafiq, S | 1 |
| Azam, S | 1 |
| Hussain, S | 1 |
| Tarar, SH | 1 |
| Al-Muhaizae, M | 1 |
| Dutta, EH | 1 |
| Behnia, F | 1 |
| Harirah, H | 1 |
| Costantine, M | 1 |
| Saade, G | 1 |
| Kent, AL | 1 |
| Jyoti, R | 1 |
| Robertson, C | 1 |
| Gonsalves, L | 1 |
| Meskell, S | 1 |
| Shadbolt, B | 1 |
| Falk, MC | 1 |
| Johnston, PG | 1 |
| Gillam-Krakauer, M | 1 |
| Fuller, MP | 1 |
| Reese, J | 1 |
| Klauser, CK | 1 |
| Briery, CM | 1 |
| Keiser, SD | 1 |
| Martin, RW | 1 |
| Kosek, MA | 1 |
| Morrison, JC | 1 |
| Kovacevic, L | 1 |
| Reid, CJ | 1 |
| Rigden, SP | 1 |
| Loe, SM | 1 |
| Sanchez-Ramos, L | 1 |
| Kaunitz, AM | 1 |
| Parkash, J | 1 |
| Khan, IA | 1 |
| Gimeno Navarro, A | 1 |
| Modesto Alapont, V | 1 |
| Morcillo Sopena, F | 1 |
| Fernández Gilino, C | 1 |
| Izquierdo Macián, I | 1 |
| Gutiérrez Laso, A | 1 |
| Campbel, AN | 1 |
| Beasley, JR | 1 |
| Kenna, AP | 1 |
| Topalian, SL | 1 |
| Ziegler, MM | 1 |
| Pedersen, S | 1 |
| Frost, L | 1 |
| Guignard, JP | 2 |
| Cantor, B | 1 |
| Tyler, T | 1 |
| Nelson, RM | 1 |
| Stein, GH | 1 |
| Niebyl, JR | 3 |
| Friedman, WF | 1 |
| Fitzpatrick, KM | 1 |
| Zenk, KE | 1 |
| Short, BL | 1 |
| Miller, MK | 1 |
| Fletcher, JR | 1 |
| Cherry, JD | 1 |
| Barrett, CT | 1 |
| Oh, W | 1 |
| Johnstone, MJ | 1 |
| Blake, DA | 1 |
| White, RD | 1 |
| Kumor, KM | 1 |
| Dubin, NH | 1 |
| Robinson, JC | 1 |
| Egner, PG | 1 |
| Lozano González, CH | 1 |
| Galindo Jiménez, P | 1 |
| Pezzotti, MA | 1 |
| Lowenberg Favela, E | 1 |
| Rudolph, AM | 1 |
| Boulley, AM | 1 |
| Dehan, M | 1 |
| Vial, M | 1 |
| Hernandorena, X | 1 |
| Ropert, JC | 1 |
| Laudignon, N | 1 |
| Lhermitte, C | 1 |
| Gabilan, JC | 1 |
| Sibony, O | 1 |
| de Gayffier, A | 1 |
| Carbillon, L | 1 |
| Oury, JF | 1 |
| Boissinot, C | 1 |
| Germain, JF | 1 |
| Jacqz-Aigrain, E | 1 |
| Blot, P | 1 |
| Pomeranz, A | 1 |
| Korzets, Z | 1 |
| Dolfin, Z | 1 |
| Eliakim, A | 1 |
| Bernheim, J | 1 |
| Wolach, B | 1 |
| Gardner, MO | 1 |
| Owen, J | 1 |
| Skelly, S | 1 |
| Hauth, JC | 1 |
| Eeg-Olofsson, O | 1 |
| Malmros, I | 1 |
| Elwin, CE | 1 |
| Steen, B | 1 |
| Bartel, J | 1 |
| Rubaltelli, FF | 1 |
| Chiozza, ML | 1 |
| Zanardo, V | 1 |
| Cantarutti, F | 1 |
| Manchester, D | 1 |
| Margolis, HS | 1 |
| Sheldon, RE | 1 |
| Mouzinho, AI | 1 |
| Rosenfeld, CR | 1 |
| Risser, R | 1 |
| Gouyon, JB | 1 |
| Benitz, WE | 1 |
| Frankel, LR | 1 |
| Stevenson, DK | 1 |
| Witter, FR | 1 |
| Dudley, DK | 1 |
| Hardie, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center, Randomized Non-inferiority Trial of Early Treatment Versus Expectative Management of Patent Ductus Arteriosus in Preterm Infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)[NCT02884219] | 273 participants (Actual) | Interventional | 2016-12-23 | Completed | |||
| Vaginal Indomethacin Versus Oral Nifedipine for Preterm Labor; a Randomized Controlled Trial[NCT04404686] | Phase 2/Phase 3 | 300 participants (Anticipated) | Interventional | 2020-10-31 | Not yet recruiting | ||
| Randomized, Placebo Controlled Trial of Indomethacin for Tocolysis[NCT01869361] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-08-01 | Withdrawn (stopped due to Due to much lower than expected numbers of eligible patients and lack of PI time, the study was not started.) | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants[NCT01755728] | Phase 3 | 19 participants (Actual) | Interventional | 2013-01-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
10 reviews available for indomethacin and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Evidence-Based Medicine; Humans; Ibuprofen; In | 2012 |
Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis.
Topics: Adult; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2005 |
Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis.
Topics: Adult; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2005 |
Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis.
Topics: Adult; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2005 |
Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis.
Topics: Adult; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2005 |
[Ibuprofen versus indomethacin in the preterm persistent patent ductus arteriosus therapy: review and meta-analysis].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echoca | 2007 |
Necrotizing enterocolitis: a review of animal models.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Bacterial Physiological Phenomena; Blood Volume; Bre | 1984 |
Preterm parturition. Prostaglandin synthetase inhibitors.
Topics: Amniotic Fluid; Animals; Aspirin; Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, P | 1981 |
Effects of prostaglandins, thromboxanes, and inhibitors of their synthesis on renal and gastrointestinal function in the newborn period.
Topics: Adult; Animals; Digestive System Physiological Phenomena; Ductus Arteriosus, Patent; Female; Humans; | 1980 |
An overview of perinatal clinical pharmacology.
Topics: Abnormalities, Drug-Induced; Analgesics; Bupivacaine; Carbamazepine; Chloramphenicol; Diazepam; Digo | 1981 |
[Drug therapy of patent ductus arteriosus in premature and newborn infants].
Topics: Apnea; Aspirin; Chloroquine; Digitalis Glycosides; Ductus Arteriosus, Patent; Humans; Indomethacin; | 1978 |
Adverse effects of drugs on the immature kidney.
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Female; Fetus; Furosemide; Glome | 1988 |
The pharmacology of neonatal resuscitation and cardiopulmonary intensive care. Part II--Extended intensive care.
Topics: Alprostadil; Cardiac Output; Coronary Circulation; Ductus Arteriosus; Humans; Indomethacin; Infant, | 1986 |
3 trials available for indomethacin and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Effect of antenatal tocolysis on neonatal outcomes.
Topics: Female; Gestational Age; Humans; Indomethacin; Infant, Newborn; Infant, Newborn, Diseases; Magnesium | 2012 |
The inhibition of premature labor with indomethacin.
Topics: Dinoprost; Double-Blind Method; Drug Evaluation; Estradiol; Female; Fetal Blood; Fetal Death; Humans | 1980 |
The inhibition of premature labor with indomethacin.
Topics: Dinoprost; Double-Blind Method; Drug Evaluation; Estradiol; Female; Fetal Blood; Fetal Death; Humans | 1980 |
The inhibition of premature labor with indomethacin.
Topics: Dinoprost; Double-Blind Method; Drug Evaluation; Estradiol; Female; Fetal Blood; Fetal Death; Humans | 1980 |
The inhibition of premature labor with indomethacin.
Topics: Dinoprost; Double-Blind Method; Drug Evaluation; Estradiol; Female; Fetal Blood; Fetal Death; Humans | 1980 |
30 other studies available for indomethacin and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study.
Topics: Bilirubin; Child; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Fetal Diseases; Hum | 2023 |
Response to Therapeutic Interventions in the NICU: Role of Sex as a Biological Variable.
Topics: Female; Humans; Indomethacin; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; | 2023 |
The effect of antenatal indomethacin on extremely preterm neonatal kidney function.
Topics: Acute Kidney Injury; Adult; Cohort Studies; Creatinine; Female; Humans; Indomethacin; Infant; Infant | 2022 |
Antenatal Bartter syndrome.
Topics: Bartter Syndrome; Chlorides; Fatal Outcome; Female; Humans; Hypokalemia; Hyponatremia; Indomethacin; | 2014 |
A Rare Disorder with Common Clinical Presentation: Neonatal Bartter Syndrome.
Topics: Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Bartter Syndrome; Biomarkers; Humans; Indometh | 2015 |
Perinatal Outcomes after Short versus Prolonged Indomethacin for Tocolysis in Women with Preterm Labor.
Topics: Adult; Drug Administration Schedule; Enterocolitis, Necrotizing; Female; Gestational Age; Humans; In | 2016 |
Does extreme prematurity affect kidney volume at term corrected age?
Topics: Cardiovascular Agents; Cardiovascular Diseases; Case-Control Studies; Female; Gestational Age; Human | 2009 |
Management of congenital nephrotic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Captopril; Combin | 2003 |
Neonatal Bartter syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bartter Syndrome; Biomarkers; Female; Humans; Indomethacin; | 2006 |
PG-synthetase inhibitors in obstetrics and after.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, | 1980 |
Life-threatening illness in those with severe mental handicap.
Topics: Female; Humans; Indomethacin; Infant, Newborn; Infant, Newborn, Diseases; Peptic Ulcer Perforation; | 1981 |
[Presumed side effects of indomethacin in 2 premature infants].
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Newborn, Diseases; | 1983 |
Drugs and the neonatal kidney.
Topics: Asphyxia Neonatorum; Captopril; Gentamicins; Humans; Hypoxia; Indomethacin; Infant, Newborn; Infant, | 1982 |
Oligohydramnios and transient neonatal anuria: a possible association with the maternal use of prostaglandin synthetase inhibitors.
Topics: Adult; Anuria; Arthritis, Juvenile; Blood Urea Nitrogen; Creatinine; Cyclooxygenase Inhibitors; Fema | 1980 |
Improved survival in the suckling rat model of group B streptococcal sepsis after treatment with nonsteroidal anti-inflammatory drugs.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Humans; Ibuprofen; Indomethacin; Infant, Newborn; | 1982 |
Nonsteroidal anti-inflammatory drugs and the treatment of neonatal sepsis due to group B streptococci.
Topics: Animals; Anti-Inflammatory Agents; Humans; Indomethacin; Infant, Newborn; Infant, Newborn, Diseases; | 1982 |
Renal functions and clinical disorders in the neonate.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Asphyxia Neonatorum; Furosemide; Humans; Indomethacin; I | 1981 |
A comparison of plasma prostaglandin levels in term and preterm labour.
Topics: Female; Humans; Hypertension, Pulmonary; Indomethacin; Infant, Newborn; Infant, Newborn, Diseases; P | 1981 |
[Persistent pulmonary hypertension in the newborn caused by prenatal use of prostaglandin inhibitors, (indomethacin). Report of a case].
Topics: Abortion, Threatened; Adult; Female; Humans; Hypertension, Pulmonary; Indomethacin; Infant, Newborn; | 1980 |
Effects of aspirin and acetaminophen in pregnancy and in the newborn.
Topics: Abnormalities, Drug-Induced; Acetaminophen; Animals; Aspirin; Blood Platelets; Female; Fetus; Humans | 1981 |
[Twin pregnancy, indomethacin and neonatal cyanosis (author's transl)].
Topics: Adult; Cyanosis; Diseases in Twins; Female; Humans; Indomethacin; Infant, Newborn; Infant, Newborn, | 1980 |
[Has the use of indomethacin during pregnancy consequences in newborn infants? Prospective study of 83 pregnant women and 115 newborn infants].
Topics: Female; Humans; Indomethacin; Infant, Newborn; Infant, Newborn, Diseases; Obstetric Labor, Premature | 1994 |
Acute renal failure in the neonate induced by the administration of indomethacin as a tocolytic agent.
Topics: Acute Kidney Injury; Adult; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn | 1996 |
Preterm delivery after indomethacin. A risk factor for neonatal complications?
Topics: Cohort Studies; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; Female; Hemorrhage; Huma | 1996 |
Convulsions in a breast-fed infant after maternal indomethacin.
Topics: Adult; Breast Feeding; Female; Humans; Indomethacin; Infant, Newborn; Infant, Newborn, Diseases; Mal | 1978 |
Effect on neonate of maternal treatment with indomethacin.
Topics: Female; Fetus; Humans; Indomethacin; Infant, Newborn; Infant, Newborn, Diseases; Maternal-Fetal Exch | 1979 |
Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn.
Topics: Adolescent; Female; Humans; Hypertension, Pulmonary; Indomethacin; Infant, Newborn; Infant, Newborn, | 1976 |
Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989.
Topics: Analysis of Variance; Cardiac Surgical Procedures; Colloids; Ductus Arteriosus, Patent; Female; Flui | 1991 |
Neonatal outcome after indomethacin treatment for preterm labor.
Topics: Apgar Score; Birth Weight; Female; Gestational Age; Humans; Indomethacin; Infant, Newborn, Diseases; | 1986 |
Fetal and neonatal effects of indomethacin used as a tocolytic agent.
Topics: Birth Weight; Female; Fetus; Humans; Indomethacin; Infant Mortality; Infant, Newborn; Infant, Newbor | 1985 |